A detailed history of Teacher Retirement System Of Texas transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Teacher Retirement System Of Texas holds 3,207 shares of MDGL stock, worth $1.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,207
Previous 2,764 16.03%
Holding current value
$1.01 Million
Previous $774,000 12.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$212.22 - $292.96 $94,013 - $129,781
443 Added 16.03%
3,207 $680,000
Q2 2024

Aug 09, 2024

BUY
$193.33 - $291.99 $24,746 - $37,374
128 Added 4.86%
2,764 $774,000
Q1 2024

May 06, 2024

BUY
$171.37 - $283.23 $27,761 - $45,883
162 Added 6.55%
2,636 $704,000
Q4 2023

Feb 07, 2024

SELL
$120.4 - $237.13 $46,354 - $91,295
-385 Reduced 13.47%
2,474 $572,000
Q3 2023

Oct 31, 2023

SELL
$146.04 - $225.78 $85,579 - $132,307
-586 Reduced 17.01%
2,859 $418,000
Q2 2023

Jul 19, 2023

SELL
$203.88 - $312.0 $49,746 - $76,128
-244 Reduced 6.61%
3,445 $796,000
Q1 2023

May 12, 2023

BUY
$231.06 - $307.08 $23,799 - $31,629
103 Added 2.87%
3,689 $894,000
Q4 2022

Feb 10, 2023

SELL
$58.39 - $296.54 $18,859 - $95,782
-323 Reduced 8.26%
3,586 $1.04 Million
Q3 2022

Nov 03, 2022

BUY
$60.57 - $79.51 $236,768 - $310,804
3,909 New
3,909 $254,000
Q2 2022

Aug 09, 2022

SELL
$58.04 - $100.2 $123,625 - $213,426
-2,130 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$55.89 - $101.89 $119,045 - $217,025
2,130 New
2,130 $209,000
Q3 2018

Nov 09, 2018

SELL
$207.3 - $300.31 $296,646 - $429,743
-1,431 Closed
0 $0
Q2 2018

Aug 06, 2018

BUY
$101.55 - $313.9 $145,318 - $449,190
1,431 New
1,431 $400,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.37B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.